No connection

Search Results

ALGS vs HYFT

ALGS
Aligos Therapeutics, Inc.
BEARISH
Price
$7.57
Market Cap
$46.6M
Sector
Healthcare
AI Confidence
85%
HYFT
MindWalk Holdings Corp.
BEARISH
Price
$1.07
Market Cap
$50.0M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ALGS
--
HYFT
--
Forward P/E
ALGS
-1.42
HYFT
--
P/B Ratio
ALGS
0.87
HYFT
4.68
P/S Ratio
ALGS
21.31
HYFT
1.78
EV/EBITDA
ALGS
0.3
HYFT
-4.06

Profitability

Gross Margin
ALGS
0.0%
HYFT
57.19%
Operating Margin
ALGS
-12907.7%
HYFT
-88.36%
Profit Margin
ALGS
0.0%
HYFT
-43.6%
ROE
ALGS
-196.91%
HYFT
-58.82%
ROA
ALGS
-69.33%
HYFT
-18.94%

Growth

Revenue Growth
ALGS
-73.1%
HYFT
52.4%
Earnings Growth
ALGS
--
HYFT
--

Financial Health

Debt/Equity
ALGS
0.1
HYFT
0.24
Current Ratio
ALGS
3.9
HYFT
3.74
Quick Ratio
ALGS
3.67
HYFT
3.4

Dividends

Dividend Yield
ALGS
--
HYFT
--
Payout Ratio
ALGS
0.0%
HYFT
0.0%

AI Verdict

ALGS BEARISH

ALGS exhibits severe financial distress, reflected in a Piotroski F-Score of 0/9 and a lack of Altman Z-Score, indicating extreme bankruptcy risk. The company reports massive negative profitability metrics, including a -12,907.69% operating margin and -196.91% ROE, alongside a 73.1% YoY revenue decline. Despite a strong analyst consensus of 'strong_buy' and a high target price of $80.25, the stock trades at a premium valuation (Price/Sales of 21.31) with no earnings or cash flow generation. Insider sentiment is neutral, and technical trends are bearish, underscoring a lack of market confidence. The combination of deteriorating fundamentals and speculative valuation creates a high-risk profile.

Strengths
Analyst consensus is strongly bullish with a $80.25 target price
Recent quarterly EPS growth shows strong momentum (+85.4% YoY, +37.2% Q/Q)
Positive earnings surprises in 2 of the last 4 quarters (average +3.87%)
Risks
Piotroski F-Score of 0/9 signals extreme financial distress and operational failure
Negative operating margin (-12,907.69%) and ROE (-196.91%) reflect deep unprofitability
73.1% YoY revenue decline indicates business contraction
HYFT BEARISH

MindWalk Holdings Corp. (HYFT) exhibits severe financial distress as evidenced by a Piotroski F-Score of 1/9, indicating critical weakness in fundamental health. While the company shows strong top-line revenue growth of 52.4% and maintains a healthy current ratio of 3.74, it is unable to translate this growth into profitability, with an operating margin of -88.36%. The stock is currently in a sharp technical downtrend, losing over 40% of its value in the last six months. Despite a high analyst target price of $4.00, the consistent failure to meet earnings estimates (0/4 beats) suggests a significant disconnect between analyst expectations and operational reality.

Strengths
Strong YoY revenue growth of 52.40%
Healthy liquidity with a current ratio of 3.74
Low leverage with a Debt/Equity ratio of 0.24
Risks
Critical financial health (Piotroski F-Score 1/9)
Severe lack of profitability with ROE at -58.82%
Consistent earnings misses (Average surprise -106.63% over last 4 quarters)

Compare Another Pair

ALGS vs HYFT: Head-to-Head Comparison

This page compares Aligos Therapeutics, Inc. (ALGS) and MindWalk Holdings Corp. (HYFT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile